Pharma CDMOs in India have brought forth a strategic shift in the ever-important drug development process for pharma companies. Today, Indian CDMOs are evolving beyond the traditional model to stay relevant with the changing market dynamics leveraging the proven CDMO 2.0 model. These players today are not just mere contract developers and manufacturers, but rather have evolved into more strategic, tech-agnostic partners offering a one-stop solution.

Similarly, the India oncology clinical trials market generated USD 571.8 million in 2025 and is projected to reach USD 1,337.5 million by 2033, growing at a robust CAGR of 11.4 percent starting in 2026. This rapid expansion has been ramping up an unprecedented demand for specialized pharmaceutical oncology clinical research consulting.

At the same time, the Pharma Clinical Research Services (CRO) market in India is experiencing rapid expansion and is projected to cross USD 3.6 billion in the coming years. This growth is being steered by the growing emphasis on prioritizing technological integration, data management, and domestic biopharma capability.

Transitioning from traditional volume-based generics to value-driven, complex therapeutics, the pharmaceutical strategy advisory consulting market in India is undergoing a major shift in 2026 with a growing focus on R&D acceleration, digital health integration, and biosimilar commercialization

As these specialized niches in the realm of pharmaceuticals have been redefining the industry at a larger scale, India is poised to showcase tremendous growth potential as it solidifies itself as the global pharmaceutical hub that will play a pivotal role in driving the much needed innovation. Recognizing the importance of CDMOs, laboratory equipment supplier, oncology clinical research consultants, and strategic advisors, India Pharma Outlook brings to you our yet another meticulously crafted “June Edition VOL. II - 2026.”